The Motley FoolT3·1mo ago
VANI Vivani Medical, Inc. Common Stock (DE)
XNAS 1.13 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
VANI
$1.13
—
Key stats
$1.13
Pre-market
$1.10
-2.66%
- 52-Week Range
- $0.92 – $1.81
- YTD
- -11.02%
- Straddle Price
- $0.60
- P/C Vol Ratio
- 6.73
- Market Cap
- $0.1B
- Open
- $1.11
- Day Range
- $1.11 – $1.15
- Volume
- 122,722
- Prev Close
- $1.11
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.13 |
| Cost of Equity (CAPM) | 11.19% (VRP-adj) |
| WACC | 11.34% |
| Volatility Risk Premium | +193.9pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -138.7% |
| Book / Price | 25.7% |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.27 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.18 |
| Bollinger Width / SMA20 | 1550.0% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | n/a | 0% | |
| Peer P/S | n/a | 0% | |
| Market Anchor (SMA50) | $1.27 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS (3845) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 36
- List Date
- 2022-08-31
- CIK
- 0001266806
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.07) (1 est.)
- Headquarters
- Alameda, CA
- Homepage
- https://www.vivani.com
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including med…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 34.06% | -2.88% | -0.83% | 9.45% | 9.95% |
| Feb | -- | -12.00% | 305.77% | -5.13% | -16.33% | 68.08% |
| Mar | -- | -9.91% | -40.13% | -2.78% | -18.03% | -17.71% |
| Apr | -- | 20.70% | -18.18% | 0.98% | 34.00% | 9.38% |
| May | -- | 20.18% | -1.81% | 21.15% | -2.94% | 9.14% |
| Jun | -- | -8.33% | -24.55% | 4.88% | -3.88% | -7.97% |
| Jul | -- | 1.61% | -1.60% | 6.35% | 5.35% | 2.93% |
| Aug | 0.00% | -25.99% | 8.26% | -13.53% | 4.51% | -5.35% |
| Sep | -42.42% | 9.68% | -4.88% | 21.55% | -8.82% | -4.98% |
| Oct | -21.98% | 1.96% | 17.49% | 11.81% | -7.38%* | 0.38% |
| Nov | -24.73% | -9.53% | 11.63% | -15.00% | -- | -9.41% |
| Dec | -39.31% | 6.65% | -20.00% | -7.52% | -- | -15.04% |
| Total | -79.48% | 14.68% | 52.05% | 15.30% | -12.74% | -2.04% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.18
SMA 50: $1.27
SMA 200: $1.26
Current: $1.13
EMA 12: $1.15
EMA 26: $1.19
MACD: -0.0425 | Signal: -0.0032
BEARISH
ADX (14): 14.82
RANGE
+DI: 19.61
−DI: 24.23
Momentum Oscillators
RSI (14): 40.74
NEUTRAL
Stoch %K: 16.67
Stoch %D: 16.08
Williams %R: -75.93
Volume & Volatility
BB Upper: $1.29
BB Lower: $1.07
NEUTRAL
OBV: 22,251,805
Vol SMA 20: 150,647
Vol ROC: -16.47%
ATR: $0.05
True Range: $0.04
HV 20: 39.3%
HV 30: 37.5%
HV 60: 48.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report - VANI
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a neutral to bullish trend, with the MACD indicating bullish momentum.
- Recent news headlines have been mostly positive, with no major negative surprises.
Primary Risks:
- High volatility could lead to increased price fluctuations.
- Options market pricing in a $0.85 move by expiration, which may be higher than usual for this stock.
Investment Thesis: VANI's recent technical and fundamental trends suggest a potentially range-bound or slightly bullish scenario. However, the high volatility and options market expectations indicate that there is still significant uncertainty surrounding the stock's short-term performance.
Recent News Sentiment Impact: The positive news headlines have contributed to a generally positive sentiment around VANI, which may be supporting the recent price action.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): NEUTRAL
- Medium-term (1-3 months): BULLISH
- Long-term (3-12 months): RANGE-BOUND
Support/Resistance Levels: The current price is near the upper band of the Bollinger Bands, which may indicate overbought conditions. Key support levels include the lower band ($1.25) and the 50-day SMA ($1.29).
Momentum Signals:
- RSI (14): 50.19 (NEUTRAL)
- MACD: Bullish momentum, with a signal line crossover above the zero line.
- Bollinger Bands: Price is near the upper band, indicating overbought conditions.
Volume Analysis: The recent volume flow has been moderate to low, which may indicate some caution among traders and investors. Institutional interest signals are mixed, with both buys and sells visible in the options market.
News & Sentiment Analysis
Recent Headlines Summary: Two positive news headlines were released recently, including a merger agreement announcement and an update on emerging growth conference presentations.
Sentiment Assessment: The aggregate sentiment is POSITIVE, driven by the recent positive news headlines.
Catalyst Identification: No major catalysts are immediately apparent, but upcoming events such as earnings announcements or product launches could provide further direction for the stock.
Market Narrative: The market narrative suggests that VANI's recent price action may be driven by a combination of technical and fundamental factors, including the positive news headlines and bullish momentum signals.
Risk & Volatility Assessment
Risk Assessment: VANI's beta is high (1.51), indicating that it tends to move more than the broader market. This increased volatility could lead to higher price fluctuations in the short term.
Volatility Regime: The current volatility regime is high, with historical volatility levels above 60%.
Options Market Signals: IV Rank: 38.7% (MEDIUM), indicating that volatility is historically medium. Put/Call Volume Ratio: 0.00 (BULLISH sentiment).
Downside Protection: Support levels include the lower band ($1.25) and the 50-day SMA ($1.29). Risk management considerations include setting stop-loss levels below these support areas.
Market Context & Positioning
Sector Performance: VANI's sector is performing relatively well, with some stocks showing strong gains.
Institutional Activity: Some institutional investors are buying into VANI, as evidenced by the recent options activity and volume flow.
Correlation Analysis: VANI's correlation with the broader market (R-squared) is 0.27, indicating a relatively low correlation.
Relative Valuation: VANI is trading within its historical range, suggesting that it may be slightly undervalued or overvalued depending on the specific valuation metric used.
Key Levels & Action Items
Critical Price Levels:
- Upper band ($1.45)
- Middle band ($1.35)
Breakout/Breakdown Levels:
- Resistance: $1.45
- Support: $1.25, $1.29 (50-day SMA)
Time-Sensitive Catalysts: No major catalysts are immediately apparent, but upcoming events such as earnings announcements or product launches could provide further direction for the stock.
Risk Management: Set stop-loss levels below the support areas ($1.25 and $1.29) to manage risk in case of a potential downturn.
Generated
News
All VANI news →
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·3mo ago
GlobeNewswire Inc.T3·9mo ago
GlobeNewswire Inc.T3·12mo ago
GlobeNewswire Inc.T3·21mo ago
BenzingaT3·27mo ago
BenzingaT3·32mo ago
BenzingaT3·32mo ago
PennyStocksT3·32mo ago
Showing 1–10 of 38
Page 1 of 4
Earnings History
12 of 12 under expected move
Avg Expected Move
65.89%
Avg Actual Move
3.01%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2023-05-15 | After-Close | 90.77% | 10.00% | 0.11x | Within |
| 2024-03-26 | After-Close | 40.43% | 1.60% | 0.04x | Within |
| 2024-05-13 | After-Close | 16.22% | 1.08% | 0.07x | Within |
| 2024-08-13 | Pre-Market | 146.85% | 0.00% | 0.00x | Within |
| 2024-11-13 | After-Close | 44.96% | 3.60% | 0.08x | Within |
| 2025-03-13 | After-Close | 117.19% | 2.83% | 0.02x | Within |
| 2025-05-13 | After-Close | 137.41% | 3.81% | 0.03x | Within |
| 2025-08-13 | After-Close | 17.86% | 0.79% | 0.04x | Within |
| 2025-11-13 | After-Close | 31.37% | 4.80% | 0.15x | Within |
| 2026-03-26 | Pre-Market | 84.07% | 4.42% | 0.05x | Within |
| 2026-05-12 | After-Close | 13.16% | 1.75% | 0.13x | Within |
| 2026-08-12 | Pre-Market | 50.36% | 1.44% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
VANI Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.60
7-DTE Move: $0.60
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 15
Put Volume: 101
P/C Volume: 6.733
BEARISH
Call OI: 2,344
Put OI: 114
P/C OI: 0.049
Total OI: 2,458
ATM Options Pricing
ATM Call: $0.47
ATM Put: $0.12
Call %: 42.0%
Put %: 11.1%
Chain Summary
Chain Volume: 456
Chain OI: 4,261
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 67th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
67%
vs own history
GEX tilt
+0.63
OI-weighted, today
Vanna tilt
+0.87
δ-sensitivity to IV
Charm tilt
-0.97
δ-decay vs time
Vanna tilt +0.87: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.97: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 284.9% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.60Oct 26
Beta Analysis
Risk Metrics
Beta: 1.4479
Alpha: -35.12%
Correlation: 0.2897
R-Squared: 8.4%
Stock Volatility: 63.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
VANI Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 65,653,250 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
2 filers$31.37K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $20.96K | 66.80% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $10.42K | 33.20% | 2026-06-30 |
1 filers$868 notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $868 | 100.00% | 2026-06-30 |
VANI Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Aaron Mendelsohn | Director | Gift (G) | −20,000 | — | EDGAR | |
| 2026-07-30 | Truc Le | Chief Operations Officer | Grant (A) | +240,000 opt | — | EDGAR | |
| 2026-07-30 | Adam Mendelsohn | Chief Executive Officer | Grant (A) | +300,000 opt | — | EDGAR | |
| 2026-07-30 | Donald Dwyer | Chief Business Officer | Grant (A) | +105,000 opt | — | EDGAR | |
| 2026-07-30 | Lisa Ellen Porter | Chief Medical Officer | Grant (A) | +120,000 RSU | — | EDGAR | |
| 2026-07-30 | Anthony Baldor | Chief Financial Officer | Grant (A) | +112,500 RSU | — | EDGAR | |
| 2026-07-28 | Daniel Bradbury | Director | Grant (A) | +7,965 opt | — | EDGAR | |
| 2026-07-16 | Gregg Williams | Director | Buy (P) | +793,650 | $1.26 | $1000.0K | EDGAR |
| 2026-06-26 | August J Moretti | Director | Grant (A) | +36,000 opt | — | EDGAR | |
| 2026-06-25 | Aaron Mendelsohn | Director | Grant (A) | +36,516 opt | — | EDGAR | |
| 2026-06-25 | Alexandra L. Popoff | Director | Grant (A) | +36,516 opt | — | EDGAR | |
| 2026-06-25 | Daniel Bradbury | Director | Grant (A) | +36,516 opt | — | EDGAR | |
| 2026-06-25 | Gregg Williams | Director | Grant (A) | +36,516 opt | — | EDGAR | |
| 2026-06-16 | Gregg Williams | Director | Buy (P) | +1,587,301 | $1.26 | $2.00M | EDGAR |
| 2026-05-19 | Gregg Williams | Director | Buy (P) | +1,587,301 | $1.26 | $2.00M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
VANI Insider Holdings
6 insiders · @ $1.13
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Gregg Williams | Director | 41,711,936 | $47.13M | $37.16M | 58 | 2026-07-16 |
| 2 | Adam Mendelsohn | Chief Executive Officer | 3,605,015 | $4.07M | $0 | 6 | 2026-07-30 |
| 3 | Aaron Mendelsohn | Director | 1,066,487 | $1.21M | $37.6K | 7 | 2026-10-19 |
| 4 | Donald Dwyer | Chief Business Officer | 55,000 | $62.1K | $63.2K | 16 | 2026-07-30 |
| 5 | Brigid Makes | Chief Financial Officer | 15,000 | $16.9K | $14.9K | 9 | 2025-05-14 |
| 6 | Alexandra L. Popoff | Director | 199 | $225 | $0 | 6 | 2026-06-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
VANI Board & Officers
As of SEC filings through Oct 19, 2026Directors 6
- Aaron Mendelsohn · since Nov 18, 2014
- Alexandra L. Popoff · since Apr 5, 2021
- Adam Mendelsohn · since Aug 30, 2022
- Gregg Williams · listed since Apr 2026
- August J Moretti · since Jun 24, 2026
- Daniel Bradbury · listed since Jun 2026
Officers 5
- Adam Mendelsohn · CEO · since Aug 30, 2022
- Anthony Baldor · Chief Financial Officer · since Jun 15, 2025
- Donald Dwyer · Chief Business Officer · since Aug 30, 2022
- Lisa Ellen Porter · Chief Medical Officer · since Aug 30, 2022
- Truc Le · Chief Operations Officer · listed since May 2024
10% owners 1
- Gregg Williams · listed since Apr 2026
Changes in the last 10 years (35)
| Jun 25, 2026 | Daniel Bradbury first listed as a director in an SEC filing |
| Jun 24, 2026 | August J Moretti became a director |
| Apr 16, 2026 | Gregg Williams first listed as a director in an SEC filing |
| Apr 16, 2026 | Gregg Williams first listed as a 10% owner in an SEC filing |
| Jun 26, 2025 | Wilford Dean Baker reported in an SEC filing no longer being a director |
| Jun 26, 2025 | Gregg Williams reported in an SEC filing no longer being a director |
| Jun 26, 2025 | Gregg Williams reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2025 | Daniel Bradbury reported in an SEC filing no longer being a director |
| Jun 15, 2025 | Anthony Baldor became Chief Financial Officer |
| Jun 10, 2025 | The company announced the departure of Brigid Makes as CFO in an SEC filing |
| May 14, 2024 | Truc Le listed as Chief Operations Officer (previously COO) in SEC filings |
| Mar 4, 2024 | Daniel Bradbury became a director |
| Aug 30, 2022 | Truc Le became COO |
| Aug 30, 2022 | Lisa Ellen Porter became Chief Medical Officer |
| Aug 30, 2022 | Joachim Eberhard Bolck became a 10% owner |
| Aug 30, 2022 | Donald Dwyer became Chief Business Officer |
| Aug 30, 2022 | Brigid Makes became CFO |
| Aug 30, 2022 | Adam Mendelsohn became a director |
| Aug 30, 2022 | Adam Mendelsohn became CEO |
| Apr 6, 2021 | Wilford Dean Baker became a director |
| Apr 5, 2021 | Alexandra L. Popoff became a director |
| Mar 30, 2021 | Scott Dunbar became Acting CEO |
| Sep 4, 2020 | Edward Jonathon Sedo became Controller |
| Sep 25, 2019 | Jessy Dana Dorn became VP-Clin & Scientific Affairs |
| Sep 1, 2018 | William Patrick Ryan became Chief Operating Officer |
| Jun 1, 2018 | Stephen D Okland listed as Chief Commercial Officer (previously Commercial VP, North America) in SEC filings |
| Jun 1, 2018 | Edward David Randolph listed as Vice President - Manufacturing (previously Vice President of Manufacturin) in SEC filings |
| Mar 26, 2018 | John T Blake became Chief Financial Officer |
| Jun 5, 2017 | William J Phd Link no longer listed as a 10% owner in SEC filings |
| May 23, 2017 | Jonathan Will McGuire first listed as a director in an SEC filing |
| May 22, 2017 | Incumed, LLC reported in an SEC filing no longer being a 10% owner |
| May 22, 2017 | Alfred E. Mann Living Trust reported in an SEC filing no longer being a 10% owner |
| Feb 28, 2017 | David Murray Jacques became VP - Research Development |
| Jan 5, 2017 | Stephen D Okland listed as Commercial VP, North America (previously Commercial V.P., North America) in SEC filings |
| Jan 5, 2017 | Edward David Randolph listed as Vice President of Manufacturin (previously VP of Manufacturing) in SEC filings |
Not reported recently (15)
- Joachim Eberhard Bolck · Last reported as a 10% owner in an SEC filing dated Apr 25, 2023
- Matthew J Pfeffer · Last reported as a director in an SEC filing dated Jul 27, 2022
- Jonathan Will McGuire · Last reported as a director in an SEC filing dated Jul 27, 2022
- Scott Dunbar · Last reported as Acting CEO in an SEC filing dated Apr 8, 2021
- Edward David Randolph · Last reported as Vice President - Manufacturing in an SEC filing dated Sep 30, 2020
- Edward Jonathon Sedo · Last reported as Controller in an SEC filing dated Sep 14, 2020
- John T Blake · Last reported as Chief Financial Officer in an SEC filing dated Feb 21, 2020
- William Patrick Ryan · Last reported as Chief Operating Officer in an SEC filing dated Feb 21, 2020
- Jessy Dana Dorn · Last reported as VP-Clin & Scientific Affairs in an SEC filing dated Feb 14, 2020
- William J Phd Link · Last reported as a director in an SEC filing dated Jun 5, 2019
- Stephen D Okland · Last reported as Chief Commercial Officer in an SEC filing dated Feb 21, 2019
- Thomas B Miller · Last reported as Chief Financial Officer in an SEC filing dated Jan 23, 2018
- Gregoire Cosendai · Last reported as VP of European Operations in an SEC filing dated Jan 8, 2018
- Robert J. Greenberg · Last reported as a director in an SEC filing dated Jan 8, 2018
- David Murray Jacques · Last reported as VP - Research Development in an SEC filing dated Jan 8, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
VANI Proposed Insider Sales (Form 144)
Latest: 2024-03-05
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-03-05 | Mendelsohn Aaron | Director | 50,186 | $187.7K | 2024-03-05 | FIDELITY BROKERAGE SERVICES LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold VANI
3 shown · $1.92M total exposure · 0.01% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.40
TTM Revenue
—
TTM Net Income
$-27.09M
TTM Op. Cash Flow
$-25.35M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-6.78M | $-0.08 | $-6.20M |
| Q4 '25 | 2025-12-31 | — | $-6.63M | $-0.09 | $-6.72M |
| Q3 '25 | 2025-09-30 | — | $-6.53M | $-0.11 | $-6.35M |
| Q2 '25 | 2025-06-30 | — | $-7.14M | $-0.12 | $-6.09M |
| Q1 '25 | 2025-03-31 | — | $-6.30M | $-0.11 | $-5.16M |
| Q4 '24 | 2024-12-31 | — | $-6.05M | $-0.11 | $-5.81M |
| Q3 '24 | 2024-09-30 | — | $-6.04M | $-0.11 | $-5.66M |
| Q2 '24 | 2024-06-30 | — | $-5.36M | $-0.10 | $-4.80M |
| Q1 '24 | 2024-03-31 | — | $-6.04M | $-0.12 | $-4.51M |
| Q4 '23 | 2023-12-31 | — | $-6.03M | $-0.11 | $-3.48M |
| Q3 '23 | 2023-09-30 | — | $-6.78M | $-0.13 | $-7.70M |
| Q2 '23 | 2023-06-30 | — | $-6.53M | $-0.13 | $-5.55M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.89
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-141.9%
ROA
-64.0%
Div Yield
0.00%
FCF Yield
-34.17%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$74.19M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
519.69K
SI % of Float
1.47%
Days to Cover
2.56
Short Vol Ratio
44.1%
Free Float
35.31M
Float %
39.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-09-22